logo
  • Home
  • News
Menu

Pfizer to buy oncology biotech in $2.3bn deal

Home / Stock Analysis / Pfizer to buy oncology biotech in $2.3bn deal
Article feature image

Pfizer to buy oncology biotech in $2.3bn deal

23 Aug Stock Analysis

Pfizer has agreed to buy oncology biotech Trillium Therapeutics in a deal worth about $2.3 billion (1.96bn) as the US drugmaker seeks to bolster its pipeline with a therapy it hopes will be transformative for blood cancers.
The pharmaceutical company will…

Click here to view the original article.

Tags:
Global, The Irish Times
Facebook Google+ Twitter Pinterest
  Previous
Next  

Related Posts

1585186655182.jpeg
+

Applied Digital (APLD): Exploring Valuation After Recent Share Price Surge

10 Oct Stock Analysis
1585187245570.jpeg
+

Zimplats Holdings Limited’s (ASX:ZIM) 27% Share Price Surge Not Quite Adding Up

10 Oct Stock Analysis

recent post

  • 1585186655182.jpeg

    Applied Digital (APLD): Exploring Valuation After

    Oct 10 2025
  • news-story.jpg

    Bitcoin’s corporate moment, ICE’s bold bet,

    Oct 10 2025
  • FI-Rob-Biederman.jpg

    Due diligence reshaping AI investing strategy

    Oct 10 2025
  • 1585187245570.jpeg

    Zimplats Holdings Limited’s (ASX:ZIM) 27% Share

    Oct 10 2025
  • news-story.jpg

    SEC’s ‘future-proofing’ push to shape how

    Oct 10 2025

Categories

  • Business
  • Crypto News
  • Investing Strategy
  • People
  • Stock Analysis

©2019.  All Rights Reserved.